UPDATED: Amgen axing up to 2,900 staffers, shuttering sites in major restructuring

John Carroll

Bracing for an expensive round of late-stage studies and potential drug launches as it ramps up work on a slate of new biosimilars, reported Tuesday evening that it plans to trim up to 15% of the company's workforce, shutting down facilities in Colorado and Washington state as it slashes up to 2,900 staffers.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS